Reports Q4 revenue $80.297M, consensus $74.91M. "We had an outstanding fourth quarter, driving record revenue and operating cash flows, achieving the best quarter ever for both our Decipher prostate and Afirma thyroid tests," said Marc Stapley, Veracyte’s chief executive officer. "Moreover, throughout 2022, we invested in our long-term growth drivers to deliver on our promise of empowering clinicians with high-value insights to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Moving into 2023, we have a clear strategy, strong financial position, and significant momentum to advance our vision of transforming cancer care for patients all over the world."
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VCYT:
- Biotech Alert: Searches spiking for these stocks today
- Veracyte: Value of test for men with high risk prostate cancer validated
- ‘Stay Long and Strong’: Billionaire Ken Fisher Snaps Up These 2 ‘Strong Buy’ Stocks
- Veracyte to present multiple Decipher urologic testing abstracts at ASCO
- Veracyte: Data show Afirma testing may help patients with thyroid nodules care